Regular monitoring of CD4+ T cell levels and the CD4+/CD8+ T cell ratios in peripheral blood could become a critical strategy for guiding treatment decisions in lung cancer patients, whether they receive radiotherapy or immunotherapy. The gene discussed is CD8A; the disease is lung carcinoma.